Analysis shows Omada members maintained weight, with minimal (0.8%) average weight change, one year after discontinuing GLP-1s for weight loss,1...
Groundbreaking Programme Tackles Weight, Symptoms and Stigma, Redefining Menopause Care for Millions WeightWatchers Introduces Comprehensive Menopause Program with Queen Latifah...
Groundbreaking Program Tackles Weight, Symptoms and Stigma, Redefining Menopause Care for Millions NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) --...
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports...
Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European UnionMARLBOROUGH, Mass. and YOKNEAM ILLIT,...
Independent Black Book Findings on Compliance, Consent, and Patient Engagement from WHX Dubai Attendees DUBAI, AE / ACCESS Newswire /...
VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the...
PARTNERING WITH PAUL & ALBRECHT PATENT LAWYERS CHEYENNE, WYOMING / ACCESS Newswire / September 8, 2025 / CS Diagnostics Corp....
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for...
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September...
Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the CompanyCHARLOTTE, N.C., Sept. 08,...
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the...
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK...
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response...
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing...
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in...
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of...
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2...
LIBERTY Endovascular Robotic System * Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System Accelerated Launch Readiness...
ALK (ALKB:DC / OMX: ALK B) today announced that real-world evidence evaluating the clinical performance of the nasal adrenaline spray...